Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Mikkel Højlund & Christoph U. Correll. (2023) Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy 24:13, pages 1463-1489.
Read now
Read now
Georgios Schoretsanitis, Jonathan M. Meyer, Andreas Conca & Christoph Hiemke. (2023) Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations. Expert Opinion on Drug Metabolism & Toxicology 19:4, pages 189-202.
Read now
Read now
Yanlin Wang, Xiaofeng Wang, Matt Harlin, Frank Larsen, Moeen Panni, Murat Yildirim, Jessica Madera, Liz Arias, Andy Forbes, Nihal Mustafa, Inez Ruiz-White & Arash Raoufinia. (2021) An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Current Medical Research and Opinion 37:11, pages 1961-1972.
Read now
Read now
Giovanni Amodeo, Chiara Candiracci, Ilaria Capecci, Sergio De Filippis, Sonia Giuliani, Giorgio Guerani, Carmine Tomasetti, Vincenzo Villari & Andrea Fagiolini. (2016) Starting aripiprazole long-acting-once-a-month early in treatment: why, how and for whom? Expert consensus and practical recommendations by a panel of Italian clinicians. Expert Opinion on Pharmacotherapy 17:16, pages 2143-2147.
Read now
Read now
Pierre Chue & James Chue. (2016) A review of aripiprazole long-acting injection. Current Medical Research and Opinion 32:3, pages 441-452.
Read now
Read now
Steven G Potkin & Adrian Preda. (2016) Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 17:3, pages 395-407.
Read now
Read now
Leslie Citrome. (2016) Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Review of Clinical Pharmacology 9:2, pages 169-186.
Read now
Read now
Articles from other publishers (19)
Antonio Vita, Andrea Fagiolini, Giuseppe Maina, Claudio Mencacci, Edoardo Spina & Silvana Galderisi. (2023) Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic. Annals of General Psychiatry 22:1.
Crossref
Crossref
Vy Thi Thanh Nguyen, Nicolas Darville & An Vermeulen. (2022) Pharmacokinetics of Long-Acting Aqueous Nano-/Microsuspensions After Intramuscular Administration in Different Animal Species and Humans—a Review. The AAPS Journal 25:1.
Crossref
Crossref
Bhaskar Rege, James McGrory, Sabina Gasper & David McDonnell. (2022) Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”. PharmacoEconomics 40:12, pages 1261-1263.
Crossref
Crossref
Xiaofeng Wang, Arash Raoufinia, Sébastien Bihorel, Julie Passarell, Suresh MallikaarjunLuann Phillips. (2022) Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia. Clinical Pharmacology in Drug Development 11:2, pages 150-164.
Crossref
Crossref
Yun TienHsiang-Ping HuangDing-Lieh LiaoShang-Chien Huang. (2022) Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan. Therapeutic Advances in Psychopharmacology 12, pages 204512532211132.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2021) Adherence, Tolerability and Effective Doses of Aripiprazole Once-monthly in the Long-term Treatment of Patients with Severe Schizophrenia. Current Pharmaceutical Design 27:39, pages 4078-4085.
Crossref
Crossref
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar & Prakash S. Masand. (2021) Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. Clinical Psychopharmacology and Neuroscience 19:3, pages 434-448.
Crossref
Crossref
Wenwen Liu, Ru Ma, Feifei Liang, Chenxin Duan, Guisen Zhang, Yin Chen & Chao Hao. (2021) New Cocrystals of Antipsychotic Drug Aripiprazole: Decreasing the Dissolution through Cocrystallization. Molecules 26:9, pages 2414.
Crossref
Crossref
Jiří Masopust. (2020) Aripiprazole in the form of long-acting intramuscular injections in the clinical practice. Psychiatrie pro praxi 21:1, pages 40-46.
Crossref
Crossref
Chiara Rapinesi, Georgios D. Kotzalidis, Lorenzo Mazzarini, Roberto Brugnoli, Stefano Ferracuti, Sergio De Filippis, Ilaria Cuomo, Gloria Giordano, Antonio Del Casale, Gloria Angeletti, Gabriele Sani & Paolo Girardi. (2019) Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review. Clinical Drug Investigation 39:8, pages 713-735.
Crossref
Crossref
Monica Aguilar & Benjamin Malcolm. (2019) Effect of long-acting aripiprazole monohydrate on inpatient encounters: A retrospective mirror image study. Mental Health Clinician 9:4, pages 258-262.
Crossref
Crossref
Masakazu Hatano, Hiroyuki Kamei, Ippei Takeuchi, Kaori Tozawa, Shinya Makino, Manako Hanya, Shigeki Yamada & Nakao Iwata. (2019) The effects of different periods of co-administration of oral and long-acting injectable aripiprazole: A propensity score analysis. Human Psychopharmacology: Clinical and Experimental 34:1, pages e2681.
Crossref
Crossref
Marjie L. Hard, Angela Y. Wehr, Yangchun Du, Peter J. Weiden, David Walling & Lisa von Moltke. (2018) Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia. Journal of Clinical Psychopharmacology 38:5, pages 435-441.
Crossref
Crossref
Jun-Yi Wu, Guo Yu & Guo-Fu Li. (2018) Model-Informed Approaches for Alternative Aripiprazole Dosing Regimens and Missed Dose Management: Towards Better Adherence to Antipsychotic Pharmacotherapy. European Journal of Drug Metabolism and Pharmacokinetics 43:4, pages 471-473.
Crossref
Crossref
Marjie L. Hard, Angela Y. Wehr, Brian M. Sadler, Richard J. Mills & Lisa von Moltke. (2018) Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil. European Journal of Drug Metabolism and Pharmacokinetics 43:4, pages 461-469.
Crossref
Crossref
Zahinoor IsmailTimothy Peters-StricklandMaia MiguelezRoss A. BakerPeter HertelAnna EramoNa JinPamela PerryRaymond SanchezRobert D. McQuadeJohn M. Kane. (2017) Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia. Journal of Clinical Psychopharmacology 37:3, pages 347-350.
Crossref
Crossref
Enrico Biagi, Enrico Capuzzi, Fabrizia Colmegna, Alessandra Mascarini, Giulia Brambilla, Alessandra Ornaghi, Jacopo Santambrogio & Massimo Clerici. (2017) Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Advances in Therapy 34:5, pages 1036-1048.
Crossref
Crossref
Arash Raoufinia, Timothy Peters-Strickland, Anna-Greta Nylander, Ross A. Baker, Anna Eramo, Na Jin, Patricia Bricmont, Jennifer Repella, Robert D. McQuade, Peter Hertel & Frank Larsen. (2017) Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. International Journal of Neuropsychopharmacology 20:4, pages 295-304.
Crossref
Crossref
Andrea de Bartolomeis, Carmine Tomasetti & Felice Iasevoli. (2015) Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs 29:9, pages 773-799.
Crossref
Crossref